Related to Positive Results Reported for Biogen Idec’s Oral MS Drug in First Phase III Study

• Scientists Say Targeting T Cells Is Appropriate for Designing Drugs for Multiple Sclerosis
  
• FDA Requests More Data on Merck Serono’s Multiple Sclerosis Candidate
  
• EU Sanctions Novartis’ Multiple Sclerosis Drug Gilenya
  
• Scientists Discover New Mechanism of Nerve Fiber Damage in MS
  
• Novartis Pays GW Pharm $5M Up Front for Sativex Rights in Multiple Territories
  
• Protagen Taps Scienion for Biomarker Panel Validation Work
  
• Research Teams Implicate GM-CSF in the Pathogenesis of Multiple Sclerosis
  
• Merck Serono Gives Up on Getting Drug Candidate for Multiple Sclerosis Approved
  
• Digna and Flamel Partner on Drug Delivery Formulations for Multiple Candidates
  
• Unilabs to Offer Companion Diagnostic Services for Biogen Idec’s Tysabri
  
• Researchers Find 29 New Genetic Variants Associated with Multiple Sclerosis
  
• Adimab Signs Separate Antibody Discovery Deals with Biogen Idec and Novo Nordisk
  
• Merck Serono Acquires Phase II-Ready Multiple Sclerosis Candidate Originally Developed by Peptimmune
  
• Japan Approves Novartis’ MS Drug Gilenya and CAPS Treatment Ilaris
  
• Merck Serono and Ono Sign Separate Agreements Worth $25M for MS and Cancer Drugs
  
• Biogen Idec and Portola Forge $45M Pact to Tackle Autoimmune and Inflammatory Diseases
  
• Biogen Idec, Samsung Establish $300M Biosimilar Joint Venture
  
• Lineagen, Fast Forward Team Up to Develop MS Tests
  
• Biogen Idec Pays Isis $29M for Option to Early-Clinical SMA Antisense Therapy
  
• EC Okays Merck Serono’s Rebif for Patients With Early Stages of MS